Ranbaxy to launch anti-diabetic drug Actos by 2012
March 15th, 2010 - 5:20 pm ICT by IANSMumbai, March 15 (IANS) Pharma major Ranbaxy Laboratories Friday said it will launch anti-diabetic drug Actos in the US by 2012.
Ranbaxy, majority owned by Japan’s Daiichi Sankyo, said it has settled litigation with the country’s Takeda Pharmaceutical over a generic equivalent version of the medicine and received a non-exclusive royalty free licence for its US patents covering Actos.
“The agreement will allow Ranbaxy Pharmaceuticals to bring to patients with diabetes a generic alternative in this therapeutic area,” vice president for sales and distribution Jim Meehan said in a regulatory filing.
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy, is based in Florida and engaged in the sale and distribution of generic and branded prescription products in the US. According to IMS Health, Actos had a $3.4 billion market in 2009.
- Ranbaxy posts $210 mn net profit - May 11, 2010
- Ranbaxy settles issue with US health regulator - Dec 21, 2011
- Daiichi eyes Ranbaxy for expanding in Africa, Latin America - Mar 12, 2010
- Ranbaxy, Russian region sign healthcare pact - Jan 31, 2011
- Competition check for FDI in pharma will help consumers: CUTS - Oct 11, 2011
- Ranbaxy sets up new manufacturing facility in S. Africa - Sep 01, 2010
- Foreign investment in pharma to face competition check - Oct 11, 2011
- Gilead's model to enhance availability of anti-AIDS drug - Feb 22, 2009
- Ranbaxy ordered to improve India, US plants - Jan 26, 2012
- The Diabetes Drugs, Avandia and Actos, Have The Same Amount of Risks - Aug 29, 2010
- Zydus Cadila buys out Biochem - Dec 21, 2011
- Drug prevents Type 2 diabetes in 70pc of high-risk individuals - Mar 24, 2011
- Ranbaxy's South African arm bags $133 million order - Dec 20, 2010
- Ranbaxy boosts presence in Africa with malaria drug - May 11, 2012
- Ranbaxy's June quarter net profit falls by 25 pc - Aug 05, 2011
Tags: actos, daiichi sankyo, diabetes, diabetic drug, equivalent version, free licence, ims health, japan, jim meehan, litigation, medicine, prescription products, ranbaxy laboratories, ranbaxy pharmaceuticals, royalty, subsidiary, takeda pharmaceutical, therapeutic area, us patents, vice president